Suppr超能文献

在含有人类1号染色体的小鼠A9细胞上表达的人类补体调节蛋白。

Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.

作者信息

Seya T, Okada M, Hara T, Matsumoto M, Miyagawa S, Oshimura M

机构信息

Department of Immunology, Center for Adult Diseases Osaka, Higashinari-ku, Japan.

出版信息

Immunology. 1991 Dec;74(4):719-24.

Abstract

The structural genes of human complement regulatory proteins are clustered on chromosome 1 at position q3.2. Human chromosome 1 was transferred into a mouse fibroblast cell line, A9 [designated as A9(neo-1)], and the surface expression of its gene products participating in complement regulation, namely C3b/C4b receptor (CR1, CD35), decay-accelerating factor (DAF, CD55), membrane co-factor protein (MCP, CD46) and C3d/EB virus receptor (CR2, CD21), were assessed using respective monoclonal antibodies by flow cytometry. CR1 became positive within 7 days of culture. MCP appeared in a small population of cells by Day 3 and, together with DAF, began to increase on Day 7. CR2 appeared on Day 14. The order of the expression was CR1 greater than DAF = MCP greater than CR2. On Day 42, however, all became negative except for MCP, which was markedly diminished. These human regulatory proteins were specifically associated with the presence of human chromosome 1, since none of them were expressed on human chromosome 12-transferred A9 cells [A9(neo-12)]. Intact A9 and A9(neo-12) cells activated human complement via the alternative pathway. The activation of this pathway was suppressed in the A9(neo-1) cells that expressed CR1, DAF and MCP. Slight protective activity was still observed in the 42-day cultured A9(neo-1) cells expressing only trace MCP. These results suggest that human complement regulators, expressed via the transferred human chromosome 1, can protect heterologous cells from complement, overcoming their ability to activate the human alternative pathway.

摘要

人类补体调节蛋白的结构基因聚集在1号染色体的q3.2位置。将人类1号染色体转入小鼠成纤维细胞系A9 [命名为A9(neo-1)],通过流式细胞术使用各自的单克隆抗体评估参与补体调节的基因产物在其表面的表达,即C3b/C4b受体(CR1,CD35)、衰变加速因子(DAF,CD55)、膜辅因子蛋白(MCP,CD46)和C3d/EB病毒受体(CR2,CD21)。CR1在培养7天内呈阳性。MCP在第3天出现在一小部分细胞中,并与DAF一起在第7天开始增加。CR2在第14天出现。表达顺序为CR1大于DAF = MCP大于CR2。然而,在第42天,除了明显减少的MCP外,所有其他蛋白均变为阴性。这些人类调节蛋白与人类1号染色体的存在特异性相关,因为它们在转入人类12号染色体的A9细胞[A9(neo-12)]上均未表达。完整的A9和A9(neo-

相似文献

本文引用的文献

1
Complement C3 receptors: structure and function.补体C3受体:结构与功能
Mol Immunol. 1984 Dec;21(12):1191-9. doi: 10.1016/0161-5890(84)90009-9.
2
The alternative pathway of complement.补体替代途径
Springer Semin Immunopathol. 1984;7(2-3):163-92. doi: 10.1007/BF01893019.
6
Membrane complement receptors specific for bound fragments of C3.
Adv Immunol. 1985;37:217-67. doi: 10.1016/s0065-2776(08)60341-7.
8
The mechanism of discordant xenograft rejection.异种移植排斥反应不一致的机制。
Transplantation. 1988 Dec;46(6):825-30. doi: 10.1097/00007890-198812000-00007.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验